Descripción de la empresa
Ping An Biomedical Co., Ltd., identified by the ticker PASW, operates primarily as a provider of supply chain management services within the apparel industry, serving markets across China, Hong Kong, Cambodia, and Europe. The company's core activities encompass a comprehensive range of logistical and operational functions, including market trend analysis, product design and development, raw material sourcing, production oversight, and quality control. Despite its operational focus on textiles, the entity is officially classified within the Consumer Cyclical sector and the Textile Manufacturing industry, a categorization that places its financial performance in direct correlation with broader consumer spending patterns and global fashion trends. The current market capitalization stands at $18.81M, while the reported annual revenue for the trailing twelve months (TTM) is $34.15M, supported by a workforce of 7 employees. These valuation and revenue figures indicate a micro-cap status, suggesting that the company operates with a very small operational footprint relative to larger industry peers. The disparity between the number of employees and the scope of international operations implies a highly specialized or asset-light business model, though the low market cap further contextualizes its position as a small-scale entity with limited capital reserves compared to established textile manufacturing giants.
Salud financiera
The financial statements for the trailing twelve months reveal a revenue of $34.15M, a net income of $-12,829,206, and an EBITDA of $-14,695,886. The substantial negative gap between the positive revenue figure and the deeply negative net income highlights a significant and burdensome cost structure where operating expenses far exceed gross profits. Furthermore, the company generated free cash flow of $-59,241,688, which indicates a severe cash burn rate that severely limits the company's financial flexibility and ability to fund operations without external financing. Profitability metrics are stark, with a gross margin of 2.8%, an operating margin of -69.6%, and a profit margin of -37.6%; these figures collectively demonstrate that the company is unable to cover its core operating costs or generate profit from its sales, with the operating margin being particularly distressed relative to the gross margin. On the liability side, the company holds $1.17M in cash against $10.47M in total debt, resulting in a debt-to-equity ratio of 23.14, which characterizes the balance sheet as highly leveraged rather than conservative. Despite the high debt load, the current ratio stands at 2.76, suggesting that the company technically possesses sufficient current assets to cover its short-term liabilities, though this liquidity buffer must be viewed in the context of the aggressive cash outflow mentioned previously. Return metrics reflect this financial distress, with a return on equity of -67.4% and a return on assets of -14.7%, revealing that management is currently destroying value rather than generating returns for shareholders or utilizing assets efficiently.
Evaluación de valoración
Trailing and forward P/E ratios are both listed as N/A, a status that arises directly from the company's negative earnings and prevents the calculation of traditional price-to-earnings multiples; the absence of a forward P/E implies that analysts cannot project a near-term earnings trajectory based on historical performance patterns. The price-to-book ratio is 0.47, indicating that the market values the company at less than half of its book value, which often suggests that the market perceives significant risks in the asset quality or that the company is fundamentally undervalued due to its poor profitability. Alternative valuation metrics provide further context, with a price-to-sales ratio of 0.55 and an EV/EBITDA of -0.89; these negative or depressed multiples suggest that investors are pricing in a high probability of continued losses or potential restructuring rather than growth. The stock has exhibited extreme volatility over the last year, trading between a 52-week high of $5.40 and a 52-week low of $0.12. Without a specific current price provided in the facts to calculate an exact percentage deviation, the range itself illustrates a massive expansion in share price, moving from a distressed low of $0.12 to a high of $5.40. The beta is listed as N/A, which means that the historical volatility data required to measure the stock's sensitivity to broader market movements is not available or calculable for this specific entity.
Growth & Income
Revenue growth year-over-year is reported at -62.0%, while earnings growth is N/A due to the lack of prior period data or positive earnings to calculate a meaningful percentage change. The contraction in revenue indicates a shrinking business or loss of market share, and since there are no positive earnings to compare, the relationship between earnings growth and revenue growth cannot be established in terms of one growing faster than the other. As the company reports a net income of $-12,829,206 and a profit margin of -37.6%, it is not a dividend payer, evidenced by a dividend yield of N/A and a payout ratio of 0.0%. Consequently, the company is not distributing any portion of its income to shareholders and instead retains all capital, although the negative earnings mean these retained earnings are effectively accumulating losses rather than fueling profitable reinvestment. The overall growth and income profile is characterized by significant revenue contraction and a complete absence of dividend income, painting a picture of a company currently focused on survival rather than expansion or shareholder return generation.